Inverse link seen for estrogen hormone therapy use and young-onset breast cancer; positive link seen for long-term use of estrogen plus progestin hormone therapy
In recent study, 23 percent of NHANES primary prevention cohort currently using lipid-lowering therapies versus 47 percent eligible under U.S. guidelines
Greatest increases in access seen among more vulnerable patient groups
eHealthcare Solutions (EHS) manages advertising on this website.
We use cookies to ensure that we give you the best experience on our website.
By continuing, you agree to the use of cookies as per the EHS Privacy Policy